Compare Stocks: NRSN, EXOZ, INMB, and IMMP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXOZ eXoZymes	$7.15 +1.6%	$6.42	$4.35 ▼ $18.40	$66.36M	2.93	6,296 shs	10,228 shs
IMMP Prima BioMed	$0.39 -1.3%	$0.40	$0.29 ▼ $3.53	$56.90M	2.25	5.98 million shs	113,468 shs
INMB INmune Bio	$2.32 +7.4%	$1.78	$1.09 ▼ $2.44	$64.39M	0.97	538,592 shs	519,820 shs
NRSN NeuroSense Therapeutics	$0.38 +7.4%	$0.62	$0.25 ▼ $1.98	$14.21M	1.62	212,575 shs	125,855 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXOZ eXoZymes	+10.00%	+18.22%	+32.33%	-29.03%	-28.02%
IMMP Prima BioMed	-0.56%	-3.07%	-2.05%	-19.51%	-76.44%
INMB INmune Bio	-3.14%	+3.85%	+9.64%	+48.97%	-8.47%
NRSN NeuroSense Therapeutics	-11.96%	-20.92%	-49.94%	-57.27%	-70.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXOZ eXoZymes	$7.15 +1.6%	$6.42	$4.35 ▼ $18.40	$66.36M	2.93	6,296 shs	10,228 shs
IMMP Prima BioMed	$0.39 -1.3%	$0.40	$0.29 ▼ $3.53	$56.90M	2.25	5.98 million shs	113,468 shs
INMB INmune Bio	$2.32 +7.4%	$1.78	$1.09 ▼ $2.44	$64.39M	0.97	538,592 shs	519,820 shs
NRSN NeuroSense Therapeutics	$0.38 +7.4%	$0.62	$0.25 ▼ $1.98	$14.21M	1.62	212,575 shs	125,855 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXOZ eXoZymes	+10.00%	+18.22%	+32.33%	-29.03%	-28.02%
IMMP Prima BioMed	-0.56%	-3.07%	-2.05%	-19.51%	-76.44%
INMB INmune Bio	-3.14%	+3.85%	+9.64%	+48.97%	-8.47%
NRSN NeuroSense Therapeutics	-11.96%	-20.92%	-49.94%	-57.27%	-70.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXOZ eXoZymes	1.00	Sell	N/A	N/A
IMMP Prima BioMed	2.00	Hold	$5.50	1,324.50% Upside
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
NRSN NeuroSense Therapeutics	2.60	Moderate Buy	$8.50	2,158.84% Upside

Current Analyst Ratings Breakdown

Latest NRSN, EXOZ, INMB, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/19/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	NRSN NeuroSense Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	IMMP Prima BioMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/17/2026	IMMP Prima BioMed	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/11/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/29/2026	EXOZ eXoZymes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXOZ eXoZymes	N/A	N/A	N/A	N/A	$0.39 per share	N/A
IMMP Prima BioMed	$6.69M	8.51	N/A	N/A	$0.63 per share	0.61
INMB INmune Bio	N/A	N/A	N/A	N/A	$0.73 per share	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.05) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXOZ eXoZymes	-$9.16M	-$1.19	N/A	N/A	N/A	N/A	-292.15%	-158.66%	N/A
IMMP Prima BioMed	-$39.78M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
INMB INmune Bio	-$45.93M	-$0.67	N/A	N/A	N/A	N/A	-82.87%	-62.23%	10/29/2026 (Estimated)
NRSN NeuroSense Therapeutics	-$11.12M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)

Latest NRSN, EXOZ, INMB, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	H2 2026	IMMP Prima BioMed	-$0.0258	N/A	N/A	N/A	$11.73 million	N/A
8/13/2026	Q2 2026	EXOZ eXoZymes	N/A	-$0.33	N/A	-$0.33	N/A	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXOZ eXoZymes	0.01	3.81	3.81
IMMP Prima BioMed	N/A	2.97	N/A
INMB INmune Bio	N/A	4.04	4.04
NRSN NeuroSense Therapeutics	N/A	0.31	0.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXOZ eXoZymes	N/A
IMMP Prima BioMed	2.32%
INMB INmune Bio	12.72%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
EXOZ eXoZymes	72.41%
IMMP Prima BioMed	3.07%
INMB INmune Bio	21.40%
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXOZ eXoZymes	29	9.28 million	2.56 million	N/A
IMMP Prima BioMed	2,021	147.37 million	142.85 million	Optionable
INMB INmune Bio	10	27.75 million	21.82 million	Optionable
NRSN NeuroSense Therapeutics	10	37.77 million	27.42 million	Not Optionable

NRSN, EXOZ, INMB, and IMMP Headlines

Recent News About These Companies

Neurosense Therapeutics (NRSN) Stock Forecast & Price Target

August 13, 2026 | investing.com

Neurosense Therapeutics Stock Price History

August 13, 2026 | investing.com

NeuroSense Issues CEO Letter to Shareholders

August 13, 2026 | prnewswire.com

Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) PT at $8.50

August 12, 2026 | americanbankingnews.com

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

August 6, 2026 | prnewswire.com

NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split

July 31, 2026 | tipranks.com

NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective

July 31, 2026 | tipranks.com

Neurosense Therapeutics is a buy, this analyst says

July 28, 2026 | cantechletter.comC

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

July 22, 2026 | prnewswire.com

Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial

July 10, 2026 | theglobeandmail.com

NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)

July 8, 2026 | nasdaq.com

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

July 6, 2026 | prnewswire.com

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

June 29, 2026 | prnewswire.com

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

June 25, 2026 | prnewswire.com

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

June 22, 2026 | prnewswire.com

NeuroSense Therapeutics (NASDAQ:NRSN) CEO Alon Ben-Noon Purchases 250,000 Shares

June 18, 2026 | insidertrades.com

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

June 11, 2026 | prnewswire.com

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

June 9, 2026 | prnewswire.com

NRSN Share News Today

May 19, 2026 | uk.investing.com

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price

April 28, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, EXOZ, INMB, and IMMP Company Descriptions

eXoZymes NASDAQ:EXOZ

$7.15 +0.11 (+1.56%)

As of 04:00 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Prima BioMed NASDAQ:IMMP

$0.39 -0.01 (-1.28%)

As of 04:00 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

INmune Bio NASDAQ:INMB

$2.32 +0.16 (+7.41%)

As of 04:00 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

NeuroSense Therapeutics NASDAQ:NRSN

$0.38 +0.03 (+7.39%)

As of 04:00 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRSN, EXOZ, INMB, and IMMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRSN, EXOZ, INMB, and IMMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRSN, EXOZ, INMB, and IMMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, EXOZ, INMB, and IMMP Company Descriptions

eXoZymes NASDAQ:EXOZ

Prima BioMed NASDAQ:IMMP

INmune Bio NASDAQ:INMB

NeuroSense Therapeutics NASDAQ:NRSN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRSN, EXOZ, INMB, and IMMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRSN, EXOZ, INMB, and IMMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRSN, EXOZ, INMB, and IMMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, EXOZ, INMB, and IMMP Company Descriptions

eXoZymes NASDAQ:EXOZ

Prima BioMed NASDAQ:IMMP

INmune Bio NASDAQ:INMB

NeuroSense Therapeutics NASDAQ:NRSN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools